We developed a simple, sensitive enzymatic assay involving the fluorogenic substrate naphthol AS-MX phosphate [(3-hydroxy-2-naphthoic acid 2,4-dimethylanilide) phosphate] to measure heat-stable alkaline phosphatase (EC 3.1.3.1), the Regan isoenzyme, in human serum. The day-to-day CV was 5.7% for a serum activity of 0.080 arbitrary units/L. Measurable amounts of enzyme were detected in most normal individuals. The mean for 51 nonsmokers was 0.068 (SD 0.037) arb. units/L; for 25 smokers it was 0.440 (SD 0.360) arb. units/L. Activity of this isoenzyme in smokers was as much as 10-fold the upper normal limit for nonsmokers. Activation of this tumor marker by smoking has not received attention hitherto. We conclude that a truly normal range can only be established among nonsmokers. The isoenzymes in smokers, nonsmokers, and pregnant women were similar in their heat stability, immunologic cross reactivity, and inhibition by L-phenylalanine.
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The Regan enzyme, a heat-stable isoenzyme of alkaline phosphatase (HSAP; EC 3.1.3.1) was first reported in 1968
by Fishman et al. (1) . This isoenzyme has been found in tumor tissue and in the serum of patients with various neoplasms. It has many characteristics in common with the placental alkaline phosphatase of pregnancy, such as heat stability, inhibition by L-phenylalanine, immunologic cross reactivity, and electrophoretic mobility (1-3). It has not only been found in neoplasms but also constitutes a small fraction of the total alkaline phosphatase activity in the serum of normal individuals (4, 5) .
Previous methods for determination of HSAP in cancer patients have involved such commonly used substrates aspnitrophenyl phosphate (6), beta-glycerophosphate (7) , indoxyl phosphate (8), beta-naphthyl phosphate (9) , and phenyl phosphate (10). These methods, however, do not consistently detect the presence of HSAP activity in the serum of normal individuals, and they discriminate poorly between normal and abnormal results.
Ideally, assuming that oncofetal gene repression normally is incomplete, an assay for a tumor marker should be sensitive enough to demonstrate detectable concentrations in serum of non-tumorous subjects. Previously, the most sensitive methods for determining HSAP have been immunological (4, (11) (12) (13) (14) 
Materials and Methods

Reagents.
Naphthol AS-MX (3-hydroxy-2-naphthoic acid Blood donors. Serum was sampled from 76 healthy individuals (51 nonsmokers and 25 smokers), from a pregnant woman, and from several patients with malignant disease.
Controls.
Sera with high and low HSAP activity were respectively pooled, frozen in 1-mL aliquots, and subsequently treated the same as patients' samples. Stored at -20 #{176}C, these were stable for longer than one year.
Stock standard.
Naphthol AS-MX, 0.75 mmol/L, was prepared by dissolving 21.9 mg of naphthol AS-MX in 100 mL of N,N-dimethylformamide. Stored in a brown bottle and protected from the light, this solution is stable for four months at 4 #{176}C.
Standard curve.
Working standards were prepared by mixing 5, 10, 15, and 20 L of the stock standard with 1-mL aliquots of heat-inactivated pooled serum. This provides standards with concentrations corresponding to 3.75, 7.50, 15.0, and 30.0 molIL.
Assay buffer. Diethanolamine, 5 mollL, was adjusted to pH 11 with hydrochloric acid. Stored at 4 #{176}C, it is stable for one year. A 10-fold dilution of this buffer is used in preparing the substrate.
The final reaction mixture, 250 L substrate plus 250 .tL of serum, will have a pH of 10.2 because of the buffering capacity of the serum.
Substrate.
Naphthol AS-MX phosphate solution, 10 tmolI L, was prepared by adding 45.1 mg (or an equivalent weight corrected for water content) to 10 mL of diethanolamine buffer (stock buffer 10-fold diluted). It should be freshly prepared daily. Alternatively, if kept frozen in aliquots and protected from light, it is stable for three months at -20 #{176}C. 
Procedures
temperature, the serum is ready to be assayed. Occasionally, the serum clots during heating, but this can be avoided by allowing the blood to clot for more than 30 mm before collecting the serum.
Assay procedure. Pre-warm Aliquots from each tube were removed from the heating bath every minute for 13 mm. Residual alkaline phosphatase activity was then determined as described.
Inhibition with L-phenylalanine.
We measured the inhibition of HSAP by L-phenylalanine according to the procedure of Fishman and Ghosh (17) as modified (18) . Figure 3 shows the heat-inactivation curves for serum from a tumor patient with above-normal HSAP activity, from a pregnant woman, from a normal healthy subject, and from a patient with an abnormally high total alkaline phosphatase activity secondary to metastasis to the bones. After an initial precipitous decline, the residual activity decreases slowly by about 2% per minute. From the Figure one can conclude that heating for 7 mm at 65 #{176}C suffices, even for samples of high initial total alkaline phosphatase activity. We tested assay performance with the two serum pools. The results are shown in Table 1 . The coefficients of variation are satisfactory for both the high and low control.
Results
A reference interval, established from data on 76 apparently healthy individuals (mostly laboratory personnel), is shown in Table 2 . However, when we divided this population into smokers and nonsmokers, significantly different ranges were obtained for the two groups (see Table 2 and Figure   4 ). Most smokers have a several-fold increase of HSAP activity over that for the normal nonsmoking population. In fact, as discussed below, the increases of HSAP in smokers was often of the same magnitude as that seen in our cancer patients. To show the relationship between the placental enzyme, the HSAP from a normal population, and that from tumor patients, we compared heat stability and the degree of inhibition of enzyme activity by L-phenylalanine (17, 18) and by rabbit anti-human placental alkaline phosphatase antibody with those of the placental enzyme.
As shown in Figure 3 and Table 3 , these properties are similar.
Mean, arb. units/L 
Discussion
The kinetic procedure we used for measuring HSAP is sensitive enough to serve as a serum tumor-marker assay. It is simple enough to be performed by any laboratory, with readily available equipment and reagents. We combined three factors to achieve this: (a) heat inactivation of all other serum alkaline phosphatases, (b) use of a substrate producing a fluorescent reaction product, and (c) a five-to 10-fold decrease in the fluorometric background reading by use of acetone as a protein precipitant. Our assay mixture contains 
Precision
is excellent and day-to-day variability is negligible. Heating serum for 7 mm at 65 #{176}C inactivates all of the alkaline phosphatase isoenzymes other than the placentallike isoenzymes. The method is 80-100 times more sensitive than kinetic methods in which phenyl phosphate is used to measure HSAP (5, 19). Although we did not systematically search for specific interfering substances, we encountered none in our assays of more than 500 serum samples, including specimens from normal subjects and from patients with various neoplastic and non-neoplastic diseases. Lipemia does not interfere. In previous reports no clearcut normal ranges emerged (4, 5, (12) (13) (14) 19) . This is not surprising in light of Figure 4 and Table 2 , which indicate that a true "normal" range can be ascertained only in nonsmoking subjects. From our data on smokers, we suggest that the reported incidence of an increase of this tumor marker in serum in the presence of various tumors needs to be redefined and the clinical usefulness of the marker reconsidered.
We are currently re-evaluating HSAP activity in nonsmoking patients with tumors. Our preliminary re-suits show that in 80-90% of such patients with abovenormal HSAP activity, the values are within the range found in smokers.
The presumed phenomenon of gene activation for this tumor marker by smoking is interesting. This is not restricted to this antigen but, as is well known, also occurs in relation to carcinoembryonic antigen (20) (21) (22) . However, our preliminary data show that increases in the placental-like alkaline phosphatase are much more dramatic, with a fourto 10-fold increase for the pack-per-day cigarette smoker, than for carcinoembryonic antigen.
